Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
- 28 February 1999
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 116 (2), 294-300
- https://doi.org/10.1016/s0016-5085(99)70125-3
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study GroupGastroenterology, 1997
- Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.Gut, 1996
- Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohnʼs diseaseEuropean Journal of Gastroenterology & Hepatology, 1996
- Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's diseaseGastroenterology, 1995
- Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resectionGastroenterology, 1995
- Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's diseaseGastroenterology, 1995
- Oral Budesonide for Active Crohn's DiseaseNew England Journal of Medicine, 1994
- BudesonideDrugs, 1992
- Classification of Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1989
- Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery.Gut, 1984